When will a generic Onglyza (saxagliptin) be available?
Onglyza’s generic (saxagliptin) availability depends on when its patents and exclusivity end and when the first abbreviated new drug application (ANDA) is approved and launched. The exact date is not provided in the information available here, so it can’t be stated precisely.
How can I find the exact expected launch date for a saxagliptin generic?
The most reliable way to confirm timing is to check:
- FDA’s “Orange Book” for Onglyza (search by ingredient: saxagliptin) to see the status of listed patents and any “patent expiration” and exclusivity notes.
- FDA ANDA approval records and labeling, which indicate when a generic has been approved.
- Ongoing manufacturer launch announcements once an ANDA is approved.
Why generic timing can change (and why it may not match patent expiry)
Even if patents/exclusivity end on a certain date, launch can be delayed by:
- FDA approval timing for specific ANDAs.
- Litigation or “carve-out” settlements that shift effective entry dates.
- Manufacturing readiness and distribution timing.
Are there generics already available in other strengths or markets?
If any saxagliptin generic has already launched, availability can vary by:
- Strength (e.g., 2.5 mg vs 5 mg)
- Pharmacy inventory and wholesaler stock
- Country/region (this is often different outside the US)
Quick check you can do right now
If you tell me your country (and the Onglyza strength you use), I can help you narrow down the most likely entry window using the standard FDA/Orange Book approach for that location.
Sources: None provided in the prompt.